Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas

NCT04049513 is registered in ClinicalTrials.gov with Malaghan Institute of Medical Research as lead sponsor.

NCT NCT04049513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04049513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas
Lead sponsor
Malaghan Institute of Medical Research
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 11, 2019
Completion date
March 31, 2029
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), lymphomas non-hodgkin's b-cell, mantle cell lymphoma (mcl), primary mediastinal b-cell lymphoma (pmbcl), transformed follicular lymphoma (tfl)